$CGTX
COGNITION THERAPEUTICS INC

2023 Q1 Form 10-K Financial Statement

#000155837023004401 Filed on March 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.543M $2.860M $13.23M
YoY Change 22.38% -54.13% 31.93%
% of Gross Profit
Research & Development $5.430M $6.440M $30.32M
YoY Change -16.69% 15.56% 63.28%
% of Gross Profit
Depreciation & Amortization $21.00K $23.00K $83.00K
YoY Change 16.67% 0.0% -10.75%
% of Gross Profit
Operating Expenses $8.973M $9.300M $43.55M
YoY Change -4.67% -21.24% 52.29%
Operating Profit -$8.973M -$43.55M
YoY Change -4.67% 52.29%
Interest Expense -$10.00K -$10.00K -$28.00K
YoY Change 11.11% -1100.0% -102.13%
% of Operating Profit
Other Income/Expense, Net $2.801M $4.128M $22.15M
YoY Change -50.86% -7.61% 31.23%
Pretax Income -$6.172M -$5.182M -$21.38M
YoY Change 66.23% -29.39% 96.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.172M -$5.182M -$21.40M
YoY Change 60.81% -29.39% 82.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21 -$0.91
Diluted Earnings Per Share -$0.21 -$0.20 -$0.91
COMMON SHARES
Basic Shares Outstanding 29.26M 23.97M 23.64M
Diluted Shares Outstanding 29.09M 23.64M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.81M $41.56M $41.56M
YoY Change -24.65% -24.05% -24.05%
Cash & Equivalents $38.81M $41.56M $41.56M
Short-Term Investments
Other Short-Term Assets $2.382M $2.413M $2.413M
YoY Change 11.46% 21836.36% 20.35%
Inventory
Prepaid Expenses $2.382M $2.413M
Receivables
Other Receivables
Total Short-Term Assets $42.80M $47.65M $47.65M
YoY Change -24.17% -19.23% -19.23%
LONG-TERM ASSETS
Property, Plant & Equipment $253.0K $233.0K $1.046M
YoY Change -3.07% 60.69% 621.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.835M $1.732M $1.732M
YoY Change 29.5%
Total Long-Term Assets $2.862M $2.778M $2.778M
YoY Change 26.86% 1815.86% 1815.86%
TOTAL ASSETS
Total Short-Term Assets $42.80M $47.65M $47.65M
Total Long-Term Assets $2.862M $2.778M $2.778M
Total Assets $45.66M $50.43M $50.43M
YoY Change -22.2% -14.73% -14.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.120M $3.216M $3.216M
YoY Change -21.94% -22.84% -22.84%
Accrued Expenses $2.115M $2.094M $2.243M
YoY Change 52.93% 19.59% 28.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.465M $7.795M $7.795M
YoY Change -2.35% -0.88% -0.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.764M $1.686M $2.381M
YoY Change -5.42%
Total Long-Term Liabilities $1.764M $1.686M $2.381M
YoY Change -5.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.465M $7.795M $7.795M
Total Long-Term Liabilities $1.764M $1.686M $2.381M
Total Liabilities $9.880M $10.18M $10.18M
YoY Change -0.76% 29.4% 29.4%
SHAREHOLDERS EQUITY
Retained Earnings -$121.6M -$115.4M
YoY Change 24.25% 22.76%
Common Stock $29.00K $29.00K
YoY Change 31.82% 31.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.78M $40.25M $40.25M
YoY Change
Total Liabilities & Shareholders Equity $45.66M $50.43M $50.43M
YoY Change -22.2% -14.73% -14.73%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$6.172M -$5.182M -$21.40M
YoY Change 60.81% -29.39% 82.63%
Depreciation, Depletion And Amortization $21.00K $23.00K $83.00K
YoY Change 16.67% 0.0% -10.75%
Cash From Operating Activities -$2.705M -$10.18M -$18.53M
YoY Change -9.47% -10183.17% 410.41%
INVESTING ACTIVITIES
Capital Expenditures $41.00K $10.00K $171.0K
YoY Change -69.4% -137.04% 533.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$41.00K -$10.00K -$171.0K
YoY Change -69.4% -62.96% 533.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 5.142M 5.546M
YoY Change -89.01% -88.91% -89.58%
NET CHANGE
Cash From Operating Activities -2.705M -10.18M -18.53M
Cash From Investing Activities -41.00K -10.00K -171.0K
Cash From Financing Activities -10.00K 5.142M 5.546M
Net Change In Cash -2.752M -5.052M -13.16M
YoY Change -14.32% -110.88% -126.57%
FREE CASH FLOW
Cash From Operating Activities -$2.705M -$10.18M -$18.53M
Capital Expenditures $41.00K $10.00K $171.0K
Free Cash Flow -$2.746M -$10.19M -$18.70M
YoY Change -12.04% -8064.06% 411.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
CY2022 dei City Area Code
CityAreaCode
412
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001455365
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22230032
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991548
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3092
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22230032
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991548
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40886
CY2022 dei Entity Registrant Name
EntityRegistrantName
COGNITION THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4365359
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2500 Westchester Ave.
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Local Phone Number
LocalPhoneNumber
481-2210
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
CGTX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
38225874
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29262587
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, PA
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41562000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54721000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3672000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1799000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2413000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2005000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
467000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
47647000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
58992000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
813000
CY2022Q4 us-gaap Other Assets
OtherAssets
1732000
CY2022Q4 us-gaap Assets
Assets
50425000
CY2021Q4 us-gaap Assets
Assets
59137000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3216000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4168000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2094000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1751000
CY2022Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1702000
CY2021Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
753000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
149000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
634000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1192000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7795000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7864000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
695000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1686000
CY2022Q4 us-gaap Liabilities
Liabilities
10176000
CY2021Q4 us-gaap Liabilities
Liabilities
7864000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991548
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22230032
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
155820000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
145453000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115401000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94004000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-199000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-198000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51273000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50425000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59137000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30324000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18572000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13227000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10026000
CY2022 us-gaap Operating Expenses
OperatingExpenses
43551000
CY2021 us-gaap Operating Expenses
OperatingExpenses
28598000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-43551000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-28598000
CY2022 cgtx Grant Income
GrantIncome
22217000
CY2021 cgtx Grant Income
GrantIncome
17447000
CY2021 cgtx Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
2209000
CY2021 cgtx Fair Value Adjustment Of Simple Agreements For Future Equity
FairValueAdjustmentOfSimpleAgreementsForFutureEquity
-2236000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-35000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-88000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
443000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-28000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-893000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22154000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16882000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-11716000
CY2021 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4532000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21397000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16248000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21398000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11727000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.13
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.13
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23640199
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5190883
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23640199
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5190883
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-68184000
CY2021 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-14465000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
84761000
CY2021 cgtx Stock Issued During Period Value Conversion Of Simple Agreements For Future Equity
StockIssuedDuringPeriodValueConversionOfSimpleAgreementsForFutureEquity
11178000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
276000
CY2021 cgtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
34000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5183000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-11716000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51273000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1618000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3572000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-11716000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
93000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3572000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5183000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
152000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
31000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
352000
CY2021 cgtx Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
2209000
CY2021 cgtx Fair Value Adjustment Of Simple Agreements For Future Equity
FairValueAdjustmentOfSimpleAgreementsForFutureEquity
-2236000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
443000
CY2022 cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
1873000
CY2021 cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
1235000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-430000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-21000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-467000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-121000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1732000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1092000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2165000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
343000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1269000
CY2022 cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
2635000
CY2021 cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
501000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-121000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18533000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3631000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1618000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
276000
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1396000
CY2021 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
268000
CY2021 cgtx Proceeds From Simple Agreements For Future Equity
ProceedsFromSimpleAgreementsForFutureEquity
8942000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
34000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5546000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53201000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13159000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49532000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54721000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5189000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41562000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54721000
CY2022 cgtx Prepayment Of Insurance Through Third Party Financing
PrepaymentOfInsuranceThroughThirdPartyFinancing
838000
CY2021 cgtx Prepayment Of Insurance Through Third Party Financing
PrepaymentOfInsuranceThroughThirdPartyFinancing
1191000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
349000
CY2022 cgtx Deferred Offering Costs Included In Accounts Payable
DeferredOfferingCostsIncludedInAccountsPayable
140000
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
84761000
CY2021 cgtx Conversion Of Simple Agreements For Future Equity Into Common Stock Amount Issued
ConversionOfSimpleAgreementsForFutureEquityIntoCommonStockAmountIssued
11178000
CY2022Q4 cgtx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
200000000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41562000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q4 cgtx Allowance For Credit Loss Grants Receivable Current
AllowanceForCreditLossGrantsReceivableCurrent
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
11178000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2022 cgtx Grant Income
GrantIncome
22217000
CY2021 cgtx Grant Income
GrantIncome
17447000
CY2022Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1702000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1686000
CY2021Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
753000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p>
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
870000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1285000
CY2022Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
900000
CY2021Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
250000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37479000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
46687000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2209000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
8942000
CY2021 cgtx Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
2209000
CY2021 cgtx Fair Value Adjustment Of Simple Agreements For Future Equity
FairValueAdjustmentOfSimpleAgreementsForFutureEquity
-2236000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1186000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1015000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
953000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
870000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000
CY2022 us-gaap Depreciation
Depreciation
83000
CY2021 us-gaap Depreciation
Depreciation
93000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2000
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
38000
CY2022Q4 cgtx Legal Reserves Professional Fees And Other Accruals Current
LegalReservesProfessionalFeesAndOtherAccrualsCurrent
324000
CY2021Q4 cgtx Legal Reserves Professional Fees And Other Accruals Current
LegalReservesProfessionalFeesAndOtherAccrualsCurrent
216000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2094000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1751000
CY2022Q4 cgtx Operating Lease Assets
OperatingLeaseAssets
813000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
813000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
149000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
695000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
844000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
203000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
163000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
209000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
221000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
222000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
155000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
87000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
126000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1020000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
176000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
844000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
172000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991548
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22230032
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6450085
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7092241
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9109
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9273
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.0082
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0183
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0187
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0422
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0067
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0106
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5640438
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12002000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
524370
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.40
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1761516
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.92
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
646072
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.62
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
77752
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.70
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3679468
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2085000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2253389
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.62
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1632000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.83
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.09
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
524370
CY2022 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
943000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1697076
CY2021 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
15424000
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1761516
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
321686
CY2022 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
1325000
CY2021 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
188000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2738000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1610000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3572000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5183000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6501000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
316000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16613000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6450085
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7092241
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-11716000
CY2021 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4532000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21397000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16248000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23640199
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5190883
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23640199
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5190883
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.13
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.13
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
156000
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
113000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19058000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16435000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19045000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
178000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
13000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21384000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10910000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-13000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-806000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-11716000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.153
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.120
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.329
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.151
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.112
CY2021 cgtx Effective Income Tax Rate Reconciliation Interest Expense Percent
EffectiveIncomeTaxRateReconciliationInterestExpensePercent
0.046
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.058
CY2021 cgtx Effective Income Tax Rate Reconciliation Fair Value Adjustment Percent
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentPercent
-0.035
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.013
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8194000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13238000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1728000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4959000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
307000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
545000
CY2022Q4 cgtx Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
178000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5687000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
354000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
165000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
13000
CY2022Q4 cgtx Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
171000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
178000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
13000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2610000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3866000
CY2022Q4 cgtx Research And Development Tax Credit Carry Forwards
ResearchAndDevelopmentTaxCreditCarryForwards
1728000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 cgtx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
200000000

Files In Submission

Name View Source Status
0001558370-23-004401-index-headers.html Edgar Link pending
0001558370-23-004401-index.html Edgar Link pending
0001558370-23-004401.txt Edgar Link pending
0001558370-23-004401-xbrl.zip Edgar Link pending
cgtx-20221231.xsd Edgar Link pending
cgtx-20221231x10k.htm Edgar Link pending
cgtx-20221231x10k001.jpg Edgar Link pending
cgtx-20221231x10k002.jpg Edgar Link pending
cgtx-20221231x10k003.jpg Edgar Link pending
cgtx-20221231x10k004.jpg Edgar Link pending
cgtx-20221231x10k005.jpg Edgar Link pending
cgtx-20221231x10k006.jpg Edgar Link pending
cgtx-20221231x10k007.jpg Edgar Link pending
cgtx-20221231x10k008.jpg Edgar Link pending
cgtx-20221231x10k009.jpg Edgar Link pending
cgtx-20221231x10k010.jpg Edgar Link pending
cgtx-20221231x10k011.jpg Edgar Link pending
cgtx-20221231x10k012.jpg Edgar Link pending
cgtx-20221231x10k013.jpg Edgar Link pending
cgtx-20221231x10k014.jpg Edgar Link pending
cgtx-20221231x10k015.jpg Edgar Link pending
cgtx-20221231x10k016.jpg Edgar Link pending
cgtx-20221231x10k017.jpg Edgar Link pending
cgtx-20221231x10k018.jpg Edgar Link pending
cgtx-20221231x10k019.jpg Edgar Link pending
cgtx-20221231x10k020.jpg Edgar Link pending
cgtx-20221231xex21d1.htm Edgar Link pending
cgtx-20221231xex23d1.htm Edgar Link pending
cgtx-20221231xex31d1.htm Edgar Link pending
cgtx-20221231xex31d2.htm Edgar Link pending
cgtx-20221231xex32d1.htm Edgar Link pending
cgtx-20221231xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
cgtx-20221231_def.xml Edgar Link unprocessable
cgtx-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cgtx-20221231x10k_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cgtx-20221231_cal.xml Edgar Link unprocessable
cgtx-20221231_lab.xml Edgar Link unprocessable